Suchergebnis | Hamburg Open Science

Facetten

8 Einträge gefunden

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
2021 - Forschungsinformationssystem des UKE - frei zugänglich
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020 - Forschungsinformationssystem des UKE
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
2020 - Forschungsinformationssystem des UKE
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
2020 - Forschungsinformationssystem des UKE
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
2019 - Forschungsinformationssystem des UKE
How to manage neutropenia in multiple myeloma.
2012 - Forschungsinformationssystem des UKE
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
2011 - Forschungsinformationssystem des UKE
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
2011 - Forschungsinformationssystem des UKE